In individual patients with FPLD insulin secretion disruption [49] or low dipeptidyl peptidase 4 (DPP4) levels were observed in addition to insulin resistance, suggesting the use of glucagon-like peptide 1 receptor agonists (GLP1) [50] to improve glycemic control and reduce the high insulin demand. Here, DPP4 is linked to Insulin resistance.